Browse CRP

Summary
SymbolCRP
NameC-reactive protein, pentraxin-related
Aliases pentraxin 1; C-reactive protein
Chromosomal Location1q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00354 Pentaxin family
Function

Displays several functions associated with host defense: it promotes agglutination, bacterial capsular swelling, phagocytosis and complement fixation through its calcium-dependent binding to phosphorylcholine. Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells.

> Gene Ontology
 
Biological Process GO:0002526 acute inflammatory response
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006801 superoxide metabolic process
GO:0006909 phagocytosis
GO:0006953 acute-phase response
GO:0008015 blood circulation
GO:0008228 opsonization
GO:0009306 protein secretion
GO:0010742 macrophage derived foam cell differentiation
GO:0010743 regulation of macrophage derived foam cell differentiation
GO:0010745 negative regulation of macrophage derived foam cell differentiation
GO:0010876 lipid localization
GO:0010883 regulation of lipid storage
GO:0010888 negative regulation of lipid storage
GO:0019915 lipid storage
GO:0032637 interleukin-8 production
GO:0032677 regulation of interleukin-8 production
GO:0032928 regulation of superoxide anion generation
GO:0032930 positive regulation of superoxide anion generation
GO:0035150 regulation of tube size
GO:0042311 vasodilation
GO:0042312 regulation of vasodilation
GO:0042554 superoxide anion generation
GO:0042742 defense response to bacterium
GO:0044057 regulation of system process
GO:0045908 negative regulation of vasodilation
GO:0050663 cytokine secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050830 defense response to Gram-positive bacterium
GO:0050880 regulation of blood vessel size
GO:0051235 maintenance of location
GO:0072593 reactive oxygen species metabolic process
GO:0072606 interleukin-8 secretion
GO:0090066 regulation of anatomical structure size
GO:0090077 foam cell differentiation
GO:0090322 regulation of superoxide metabolic process
GO:0098542 defense response to other organism
GO:1903522 regulation of blood circulation
GO:1903523 negative regulation of blood circulation
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000379 positive regulation of reactive oxygen species metabolic process
GO:2000482 regulation of interleukin-8 secretion
Molecular Function GO:0001846 opsonin binding
GO:0001848 complement binding
GO:0001849 complement component C1q binding
GO:0030169 low-density lipoprotein particle binding
GO:0033265 choline binding
GO:0050750 low-density lipoprotein particle receptor binding
GO:0070325 lipoprotein particle receptor binding
GO:0070405 ammonium ion binding
GO:0071813 lipoprotein particle binding
GO:0071814 protein-lipid complex binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-173623: Classical antibody-mediated complement activation
R-HSA-166658: Complement cascade
R-HSA-166786: Creation of C4 and C2 activators
R-HSA-168256: Immune System
R-HSA-166663: Initial triggering of complement
R-HSA-168249: Innate Immune System
Summary
SymbolCRP
NameC-reactive protein, pentraxin-related
Aliases pentraxin 1; C-reactive protein
Chromosomal Location1q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CRP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CRP and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28648699Uveal MelanomaInhibit immunity; Resistant to immunotherapyEighty-six patients were treated with PD-1 inhibitors only (n = 54 for pembrolizumab, n = 32 for nivolumab) with a centrally confirmed response rate of 4.7%. Patients with elevated CRP and LDH and a REC <1.5% were at highest risk for disease progression and death (p = 0.001).
Summary
SymbolCRP
NameC-reactive protein, pentraxin-related
Aliases pentraxin 1; C-reactive protein
Chromosomal Location1q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CRP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCRP
NameC-reactive protein, pentraxin-related
Aliases pentraxin 1; C-reactive protein
Chromosomal Location1q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CRP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.2020.215
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0820.957
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)872.1710.0908
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5830.375
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5460.605
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6240.597
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.770.49
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5730.766
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6740.712
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0010.604
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.9380.225
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4270.27
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CRP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.5010.50.135
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.2018.20.274
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCRP
NameC-reactive protein, pentraxin-related
Aliases pentraxin 1; C-reactive protein
Chromosomal Location1q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CRP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCRP
NameC-reactive protein, pentraxin-related
Aliases pentraxin 1; C-reactive protein
Chromosomal Location1q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CRP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CRP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCRP
NameC-reactive protein, pentraxin-related
Aliases pentraxin 1; C-reactive protein
Chromosomal Location1q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CRP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCRP
NameC-reactive protein, pentraxin-related
Aliases pentraxin 1; C-reactive protein
Chromosomal Location1q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CRP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCRP
NameC-reactive protein, pentraxin-related
Aliases pentraxin 1; C-reactive protein
Chromosomal Location1q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CRP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCRP
NameC-reactive protein, pentraxin-related
Aliases pentraxin 1; C-reactive protein
Chromosomal Location1q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CRP collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CRP.
ID Name Drug Type Targets #Targets
DB03945N,N,N-Trimethyl-2-(phosphonooxy)ethanaminiumSmall MoleculeCRP, ELSPBP12
DB05744CRx-139Small MoleculeCRP, IL10, IL6, TNF4